CMCaitlyn Meinzer

Caitlyn Meinzer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caitlyn Meinzer has a total of 229 co-authors. Here are the top co-authors by number of shared publications:

  • Adam Baker

    Ralph H. Johnson Veterans Affairs Health Care System, Charleston, SC (N.J.S., C.S., K.C., J.B., G.S., C.F., A.B., J.G., A.A., K.H., D.T., V.R.).

    2 shared publications
  • Christian Finetto

    Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC 29425, USA

    2 shared publications
  • Christian Schranz

    Department of Paediatric Surgery, Medical University of Graz, Auenbruggerplatz 34, 8036, Graz, Austria

    2 shared publications
  • Craig A. Velozo

    Craig A. Velozo, PhD, OTR/L, FAOTA, is Professor and Division Director, Division of Occupational Therapy, Department of Rehabilitation Sciences, College of Health Professions, Medical University of South Carolina, Charleston;

    2 shared publications
  • Gabrielle Scronce

    Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC 29425, USA

    2 shared publications
  • Jenna Blaschke

    Division of Occupational Therapy, Department of Rehabilitation Sciences, Medical University of South Carolina, Charleston, USA

    2 shared publications

Latest Publications

  • Designing a phase‐III time‐to‐event clinical trial using a modified sample size formula and Poisson‐Gamma model for subject accrual that accounts for the lag in site initiation using the PERT distribution

    by Virginia B. Shipes, Caitlyn Meinzer, Bethany J. Wolf, Hong Li, Mathew J. Carpenter, Hooman Kamel, Renee H. Martin

    A priori estimation of sample size and subject accrual in multi-site, time-to-event clinical trials is often challenging. Such trials are powered based on the number of events needed to detect a clinically significant difference. Sample size based on number of events relates to the expected duration of observation time for each subject. Temporal patterns in site initiation and subject enrollment ultimately affect when subjects can be accrued into the study. Lag times are common as the site start-up process optimizes, resulting in delays that may curtail observational follow-up and therefore undermine power. The proposed method introduces a Program Evaluation and Review Technique (PERT) model into the sample size estimation which accounts for the lag in site start-up. Additionally, a PERT model is introduced into a Poisson-Gamma subject accrual model to predict the quantity of study sites needed. The introduction of the PERT model provides greater flexibility in both a priori power assessment and planning the number of sites, as it specifically allows for the inclusion of anticipated delays in site start-up time. This model results in minimal power loss even when PERT distribution inputs are misspecified compared to the traditional assumption of simultaneous start-up for all sites. Together these updated formulations for sample size and subject accrual models offer an improved method for designing a multi-site time-to-event clinical trial that accounts for a flexible site start-up process.

  • Open Access

    Effect of novel training to normalize altered finger force direction post-stroke: study protocol for a double-blind randomized controlled trial

    by Na Jin Seo, Derek G. Kamper, Viswanathan Ramakrishnan, Jillian B. Harvey, Christian Finetto, Christian Schranz, Gabrielle Scronce, Kristen Coupland, Keith Howard, Jenna Blaschke, et al.

    Background: Functional task performance requires proper control of both movement and force generation in three-dimensional space, especially for the hand. Control of force in three dimensions, however, is not explicitly treated in current physical rehabilitation. To address this gap in treatment, we have developed a tool to provide visual feedback on three-dimensional finger force. Our objective is to examine the effectiveness of training with this tool to restore hand function in stroke survivors. Methods: Double-blind randomized controlled trial. All participants undergo 18 1-h training sessions to practice generating volitional finger force of various target directions and magnitudes. The experimental group receives feedback on both force direction and magnitude, while the control group receives feedback on force magnitude only. The primary outcome is hand function as measured by the Action Research Arm Test. Other outcomes include the Box and Block Test, Stroke Impact Scale, ability to direct finger force, muscle activation pattern, and qualitative interviews. Discussion: The protocol for this clinical trial is described in detail. The results of this study will reveal whether explicit training of finger force direction in stroke survivors leads to improved motor control of the hand. This study will also improve the understanding of neuromuscular mechanisms underlying the recovery of hand function. Trial registration: ClinicalTrials.gov NCT03995069. Registered on June 21, 2019


  • Open Access

    Concomitant sensory stimulation during therapy to enhance hand functional recovery post stroke

    by Na Jin Seo, Viswanathan Ramakrishnan, Michelle L. Woodbury, Leonardo Bonilha, Christian Finetto, Christian Schranz, Gabrielle Scronce, Kristen Coupland, Jenna Blaschke, Adam Baker, et al.

    Background: Post-stroke hand impairment is prevalent and persistent even after a full course of rehabilitation. Hand diminishes stroke survivors’ abilities for activities of daily living and independence. One way to improve treatment efficacy is to augment therapy with peripheral sensory stimulation. Recently, a novel sensory stimulation, TheraBracelet, has been developed in which imperceptible vibration is applied during task practice through a wrist-worn device. The objective of this trial is to determine if combining TheraBracelet with hand task practice is superior to hand task practice alone. Methods: A double-blind randomized controlled trial will be used. Chronic stroke survivors will undergo a standardized hand task practice therapy program (3 days/week for 6 weeks) while wearing a device on the paretic wrist. The device will deliver TheraBracelet vibration for the treatment group and no vibration for the control group. The primary outcome is hand function measured by the Wolf Motor Function Test. Other outcomes include the Box and Block Test, Action Research Arm Test, upper extremity use in daily living, biomechanical measure of the sensorimotor grip control, and EEG-based neural communication. Discussion: This research will determine clinical utility of TheraBracelet to guide future translation. The TheraBracelet stimulation is delivered via a wrist-worn device, does not interfere with hand motion, and can be easily integrated into clinical practice. Enhancing hand function should substantially increase stroke survivors' independence and quality of life and reduce caregiver burden. Trial registration: NCT04569123. Registered on September 29, 2020


  • Liver Transplantation for Acetaminophen-Induced Acute Liver Failure: Role of Psychiatric Comorbidity in Listing Decisions and Outcomes

    by for the Acute Liver Failure Study Group, Okeefe L. Simmons, Caitlyn Meinzer, Jody Rule, William M. Lee


  • Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints

    by Zhenning Yu, Viswanathan Ramakrishnan, Caitlyn Meinzer

    Multi-arm multi-stage designs, in which multiple active treatments are compared to a control and accumulated information from interim data are used to add or remove arms from the trial, may reduce development costs and shorten the drug development timeline. As such, this adaptive update is a natural complement to Bayesian methodology in which the prior clinical belief is sequentially updated using the observed probability of success. Simulation is often required for planning clinical trials to accommodate the complexity of the design and to optimize key design characteristics. This paper addresses two key limiting factors in simulations, namely the computational burden and the time needed to obtain results. We first introduce a generic process for simulating Bayesian multi-arm multi-stage designs with binary endpoints. Then, to address the computational burden and time, we optimize the method for calculating the posterior probability and posterior predictive probability of success.


  • Open Access

    Bayesian dose selection design for a binary outcome using restricted response adaptive randomization

    by Caitlyn Meinzer, Renee Martin, Jose I. Suarez

    In phase II trials, the most efficacious dose is usually not known. Moreover, given limited resources, it is difficult to robustly identify a dose while also testing for a signal of efficacy that would support a phase III trial. Recent designs have sought to be more efficient by exploring multiple doses through the use of adaptive strategies. However, the added flexibility may potentially increase the risk of making incorrect assumptions and reduce the total amount of information available across the dose range as a function of imbalanced sample size. To balance these challenges, a novel placebo-controlled design is presented in which a restricted Bayesian response adaptive randomization (RAR) is used to allocate a majority of subjects to the optimal dose of active drug, defined as the dose with the lowest probability of poor outcome. However, the allocation between subjects who receive active drug or placebo is held constant to retain the maximum possible power for a hypothesis test of overall efficacy comparing the optimal dose to placebo. The design properties and optimization of the design are presented in the context of a phase II trial for subarachnoid hemorrhage. For a fixed total sample size, a trade-off exists between the ability to select the optimal dose and the probability of rejecting the null hypothesis. This relationship is modified by the allocation ratio between active and control subjects, the choice of RAR algorithm, and the number of subjects allocated to an initial fixed allocation period. While a responsive RAR algorithm improves the ability to select the correct dose, there is an increased risk of assigning more subjects to a worse arm as a function of ephemeral trends in the data. A subarachnoid treatment trial is used to illustrate how this design can be customized for specific objectives and available data. Bayesian adaptive designs are a flexible approach to addressing multiple questions surrounding the optimal dose for treatment efficacy within the context of limited resources. While the design is general enough to apply to many situations, future work is needed to address interim analyses and the incorporation of models for dose response.


  • What Information Will a Statistician Need to Help Me With a Sample Size Calculation?

    by Caitlyn Ellerbe, Charles Wolfe, Anthony Rudd, Kate Tilling, Yi-Juan Hu, Amand F. Schmidt, Frank Dudbridge, Michael V. Holmes, James M. Brophy, Vinicius Tragante, et al.


  • Two‐year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study

    by Robert J. Fontana, Caitlyn Ellerbe, Valerie E. Durkalski, Amol Rangnekar, Rajender K. Reddy, Todd Stravitz, Brendan McGuire, Timothy Davern, Adrian Reuben, Iris Liou, et al.

    Background & Aims: The long‐term clinical outcomes in initial survivors with acute liver failure (ALF) are not well known. The aim of this study was to provide an overview of the 2‐year clinical outcomes among initial survivors and liver transplant (LT) recipients that were alive 3 weeks after enrolment in the Acute Liver Failure Study Group (ALFSG).Methods: Outcomes in adult ALFSG patients that were enrolled between 1998 and 2010 were reviewed.Results: Two‐year patient survival was significantly higher in the 262 LT recipients (92.4%) compared to the 306 acetaminophen (APAP) spontaneous survivors (SS) (89.5%) and 200 non‐APAP SS (75.5%) (P < 0.0001). The causes of death were similar in the three groups but the time to death was significantly longer in the LT recipients (P < 0.0001). Independent predictors of 2‐year mortality in the APAP group were a high serum phosphate level and patient age (c‐statistic = 0.65 (0.54, 0.76)), patient age and days from jaundice to ALF onset in the non‐APAP group (c‐statistic = 0.69 (0.60, 0.78)), and patient age, days from jaundice, and higher coma grade in the LT recipients (c‐statistic = 0.74 (0.61, 0.87)). The LT recipients were significantly more likely to be employed and have a higher educational level (P < 0.05).Conclusions: Two‐year outcomes in initial survivors of ALF are generally good but non‐APAP patients have a significantly lower survival which may relate to pre‐existing medical comorbidities. Spontaneous survivors with APAP overdose experience substantial morbidity during follow‐up from ongoing psychiatric and substance abuse issues.